Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alcon IOLs Drive Surgical Sales In Q1 As Eye Laser Revenues Dim

This article was originally published in The Gray Sheet

Executive Summary

Alcon intraocular lens sales growth in the first quarter helped offset declining ophthalmic laser revenue and drive overall surgical device sales ahead 10.6% to $580.7 million in Q1, the firm reported April 25

You may also be interested in...



Alcon picks up WaveLight

Ophthalmic device maker Alcon expands its refractive laser business via the $90 million purchase of German firm WaveLight, announced July 16. WaveLight's Allegretto refractive eye laser "offers the fastest ablation speed on the market today," Alcon notes. The purchase will "provide additional clinical solutions and laser technology to better support our cataract and refractive customers," the firm explains. Alcon, which offers the Ladar6000 excimer laser and CustomCornea wavefront system for custom ablation procedures, issued a safety alert on the system in February and has initiated corrective action to address the potential for "central islands" following custom myopia laser procedures (1"The Gray Sheet" April 30, 2007, p. 6). Wachovia analyst Larry Biegelsen notes in a July 16 report that he expects Alcon to adopt Allegretto as its flagship eye laser following the acquisition. The deal also makes Alcon the second largest laser refractive franchise behind Advanced Medical Optics, Biegelsen says. Under the terms of the deal, Alcon will pay about $13.80 per share for WaveLight, a roughly 15% premium over its July 13 closing price of $12.00...

Alcon picks up WaveLight

Ophthalmic device maker Alcon expands its refractive laser business via the $90 million purchase of German firm WaveLight, announced July 16. WaveLight's Allegretto refractive eye laser "offers the fastest ablation speed on the market today," Alcon notes. The purchase will "provide additional clinical solutions and laser technology to better support our cataract and refractive customers," the firm explains. Alcon, which offers the Ladar6000 excimer laser and CustomCornea wavefront system for custom ablation procedures, issued a safety alert on the system in February and has initiated corrective action to address the potential for "central islands" following custom myopia laser procedures (1"The Gray Sheet" April 30, 2007, p. 6). Wachovia analyst Larry Biegelsen notes in a July 16 report that he expects Alcon to adopt Allegretto as its flagship eye laser following the acquisition. The deal also makes Alcon the second largest laser refractive franchise behind Advanced Medical Optics, Biegelsen says. Under the terms of the deal, Alcon will pay about $13.80 per share for WaveLight, a roughly 15% premium over its July 13 closing price of $12.00...

B&L’s MoistureLoc Worldwide Recall: Firm Ties Formulation To Infection

With evidence pointing to the basic formulation of Bausch & Lomb's ReNu with MoistureLoc contact lens solution as a contributing factor in an outbreak of serious eye infections, the company bit the bullet May 15 and issued a permanent, worldwide recall of the lucrative product

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel